Welcome to HEPAVAC’s presentations at CIMT Annual Meeting 2015 (May 11– May 13) in Mainz, Germany: Monday, May 17.00 – 19.00, East Foyer Poster presentation: Cancer vaccine development for hepatocellular carcinoma-HEPAVAC (Poster No. […]
The first annual meeting of the HEPAVAC collaborative project took place last 15th and 16th October in Tuebingen, co-hosted by CureVac and Immatics at their headquarters. More than 20 members […]
Welcome to HEPAVAC’s presentations at the “14th International Conference on Progress in Vaccination against Cancer – PIVAC-14 (Sept 24 – 26) in Rome, Italy: Thursday, Sept 25 12.35pm–2.35pm Poster presentation: […]
Welcome to HEPAVAC’s presentations at the “Cancer Bio-Immunotherapy in Siena – XIIth NIBIT Meeting” (Oct 9 – 11) in Siena, Italy: Saturday, Oct 11 11.00 am Invited oral presentation: Cancer […]
July 16, 2014, HEPAVAC’s Vice-Coordinator IMMATICS received € 22 million as final tranche of funding to complete phase 3 study with IMA901, in patients with renal cell carcinoma (RCC), and […]
Welcome to HEPAVAC’s presentations at CIMT Annual Meeting 2014 (May 6 – May 8) in Mainz, Germany: Tuesday, May 6: 3pm – 5.30pm, East Foyer Poster presentation: Cancer vaccine development […]
HEPAVAC kick-off meeting press release was released on the Alpha Galileo website, www.alphagalileo.org, the major source of scientific breaking news. – English version: >>View – Italian version: >>View
The HEPAVAC project has kicked off! HEPAVAC partners gathered in Naples on November 14, 2013. After quick celebrations, the Group started to work in order to achieve all the Meeting’s […]
The HEPAVAC Vice-Coordinator Center Immatics Biotechnologies GmbH, Tuebingen, Germany received an ethics approval to collect tumor, plasma and blood samples during the preclinical phase of the HEPAVAC project.
The HEPAVAC Center Eberhard Karls Universität, Tuebingen, Germany received an ethics approval to collect tumor, plasma and blood samples during the preclinical phase of the HEPAVAC project.